Clinigen

The demand for Post-Trial Access (PTA) programs is rising rapidly, but how can organisations navigate the operational complexities and future considerations of ensuring continued patient access to investigational treatments? Join Nicky Wisener (VP Business Development, Clinigen) and Carole Kenyon (Program Director, Clinigen) for the opening session at the 4th Clinigen Insights Conference, 26-27 February in Windsor. Don't miss this opportunity to gain practical strategies for optimising PTA programs and supporting patients beyond clinical trials. Spaces still available, register here -  https://lnkd.in/e8MNczk9 #ClinigenInsights #PostTrialAccess #ClinicalTrials #PatientAccess #HealthcareInnovation

Join us at the 4th Clinigen Insights Conference! Our exclusive event on 26–27 February 2025 in Windsor, UK brings together thought leaders, innovators, and industry experts from around the world to share insights and discuss the latest trends in Managed Access. We are also excited to announce Prof Kate Williams as our evening speaker. Internationally renowned historian, author, and broadcaster, Prof. Williams will provide a fascinating look into Windsor’s rich heritage, adding a unique historical perspective to our conference experience. Click here to register - https://lnkd.in/e8MNczk9 #Clinigen #ClinigenInsightsConference #ManagedAccess #EarlyAccess #ExpandedAccess #PharmaceuticalIndustry #HealthcareInnovation #AccessToMedicines

Exciting News! Clinigen has acquired a minority stake in Tepsivo, a leader in digital pharmacovigilance, to empower our clients with greater choice and access to AI-powered compliance solutions. Through this strategic partnership our clients can access Tepsivo's integrated automated pharmacovigilance platform linked with their established global network, for a more modern and efficient approach to managing global pharmacovigilance operations. Read more here https://lnkd.in/d3ZxTmSi #PharmaServices #pharmacovigilance #compliance #PatientSafety #DigtialPharmacovigilance #ArtificialIntelligence

Navigating the new EU Health Technology Assessment Regulation (HTAR)? The Joint Scientific Consultation (JSC) process is key to aligning your clinical development strategy with EMA and joint clinical assessments (JCAs). Ascenian, a Clinigen company, can help you succeed by providing: ✔ Strategic advice for JCAs & HTAs ✔ EMA-aligned submissions ✔ Engagement with clinical experts & patients Read the white paper from Ascenian to discover how they can support your journey. Contact susanne michel to receive your copy. #Clinigen #HTAR #ClinicalDevelopment #MarketAccess 

Clinigen Lifecycle Services with Shellie Cholke and La'Vern (Browne) George, MSCR are looking forward to meeting you at DIA's Global Pharmacovigilance and Risk Management Strategies Conference in Baltimore, USA from 27th to 29th January!     Clinigen Lifecycle Services are a full-service, high-quality global provider of Pharmacovigilance and Medical Information services operating from early development through to post-marketing on a global scale.    Putting a premium on deep experience, hands-on customer service and flexible methodologies, we guide our customers every single day. DIA #Riskmanagement  #pharmacovigilance #safetyregulations #regulatory experts #DIAConference #Clinigenlifecycleservices Kinesys Consulting Ltd

We're thrilled to announce the 4th Clinigen Insights Conference, bringing together thought leaders, innovators, and industry experts to discuss the latest advancements in 'Managed Access: From Concept to Action.' This year's theme dives deeper into the journey of Managed Access Programs — from strategic planning and regulatory considerations to practical implementation and real world insight into patients experience. When: 26–27 February 2025 Where: Windsor, UK Read the full agenda and RSVP: https://lnkd.in/e8MNczk9   Only a few places left – be quick to register!   #managedaccess #expandedaccess #earlyaccess #realworlddata

A heartfelt thank you to the #HealthcareProfessionals who make it possible to deliver critical treatments to patients every day - your dedication changes lives.   Clinigen is proud to support better patient outcomes by enabling efficient and reliable access to essential medicines through Clinigen Direct. Find out more: www.clinigendirect.com #PatientCare #ManagedAccessPrograms

Happy holidays from the Clinigen community to yours. Wishing you health, joy and peace this festive season. #HappyHolidays #PharmaServices #HappyNewYear

Climate change is a global health crisis, and the #pharmaceutical industry produces 55% more #GreenhouseGasEmissions than the automotive industry.   Tom Rose, SVP Clinical Trial Sourcing, discusses how to decarbonise pharma services while prioritising patient access and profitability. Read his latest insights in Clinical Trials Insights magazine: https://lnkd.in/dga5V46j #PharmaServices #Sustainability #DecarbonisingHealthcare #PatientAccess

Did you know that an estimated 90% of rare diseases lack approved treatments? For patients facing life-threatening conditions, waiting years for a drug to become available isn’t an option. In our latest white paper, Lauren Heiser explores how Managed Access Programs (MAPs) provide early access to groundbreaking treatments, serving as a lifeline for patients to access investigational treatments before regulatory approval. Learn how MAPs are reshaping rare disease treatment - download our white paper today: https://lnkd.in/etEfUxJ2 #RareDisease #ManagedAccessPrograms #OrphanDrugs #Innovation #PatientCare